Idiopathic pulmonary fibrosis (IPF) is a disease of progressive interstitial fibrosis, which leads to severe debilitation and eventually respiratory failure and death. Protein folding stress in the endoplasmic reticulum (ER stress) triggers the unfolded protein response (UPR), which has been implicated in IPF. The most deeply conserved mediator of the UPR is IRE1?, a bifunctional kinase/endoribonuclease that mediates XBP1 mRNA splicing, degradation of ER-localized mRNAs (RIDD), and degradation of the microRNA miR-17. Under severe ER stress, IRE1? hyperactivity promotes cell death, a condition termed the terminal UPR. A parsimonious view holds that the terminal UPR causes ongoing alveolar epithelial cell death which leads ultimately to fibrosis. The laboratory of Dr. Feroz Papa (co-mentor) developed and characterized Kinase Inhibiting RNase Attenuator (KIRA) compounds that inhibit all the major functions of IRE1?. We previously showed that mice treated with KIRA compounds were protected from bleomycin-induced fibrosis. In new preliminary data, a mono- selective KIRA compound decreased miR-17 degradation, TGF? signaling and the senescence-associated secretory phenotype (SASP) in the lung epithelium after bleomycin. In fibrotic mouse lungs and human IPF lungs, these IRE1?-regulated pathological gene signatures were preferentially found in dysfunctional progenitor cells. These results challenge the current paradigm that the UPR contributes to fibrosis exclusively through cell death. Instead, the central hypothesis of this proposal is that hyperactivation of IRE1? in injured epithelial progenitor cells triggers a network of mutually reinforcing fibrotic pathways, including gene repression by miR- 17, senescence, and TGF? signaling.
Specific Aim 1 will test the hypothesis that IRE1? is necessary and sufficient for epithelial progenitor cell dysfunction by interrogating the effects of chemical or genetic inhibition of IRE1? in the bleomycin model and two genetic models of fibrosis based on senescence (Sin3a knockout) and ER stress (SftpcC121G).
Specific Aim 2 will test the hypothesis that IRE1? regulates progenitor cell dysfunction through miR-17 using conditional deletion and conditional overexpression mice. The training plan is focused on the skills and concepts of lung regeneration and developmental biology, in vitro models of lung biology, epithelial cell dysfunction, and responsible laboratory management. Training will include didactic courses, focused symposia, and international conferences. The primary mentor and co-mentor are Dr. Dean Sheppard and Dr. Feroz Papa, both accomplished physician-scientists with long track records of mentorship. Dr. Auyeung has laboratory and office space at the UCSF Mission Bay campus, a fertile environment for collaboration with ready access to the facilities and equipment necessary for this research. In summary this Career Development Award application merges an exceptional candidate, an innovative and tractable research plan, rigorous training, and the support of world-class physician-scientists into a powerful springboard for the launch of a productive and independent career with high impact on lung disease.

Public Health Relevance

Idiopathic pulmonary fibrosis (IPF) is a devastating disease of relentless scarring in the lungs, which leads to severe debilitation and eventually respiratory failure and death. The cause of IPF is not known, and there are few treatments available. This project explores one of the underlying mechanisms of IPF, and how manipulating a cellular stress response pathway might enable progenitor cells to repair the lung, rather than promote scar tissue.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08HL157654-01
Application #
10189421
Study Section
NHLBI Mentored Clinical and Basic Science Review Committee (MCBS)
Program Officer
Kalantari, Roya
Project Start
2021-03-15
Project End
2026-02-28
Budget Start
2021-03-15
Budget End
2022-02-28
Support Year
1
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143